# Study of Apatinib and MASCT in Patients With Advanced Solid Tumors

> **NCT02844881** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The First People's Hospital of Lianyungang** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Excluding T Cell Lymphoma

## Interventions

- **DRUG:** Apatinib
- **BIOLOGICAL:** MASCT

## Key facts

- **NCT ID:** NCT02844881
- **Lead sponsor:** The First People's Hospital of Lianyungang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02844881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02844881, "Study of Apatinib and MASCT in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02844881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*